Synthetic Cathinones Induce Cell Death in Dopaminergic SH-SY5Y Cells via Stimulating Mitochondrial Dysfunction. by Leong, HS et al.
 International Journal of 
Molecular Sciences
Article
Synthetic Cathinones Induce Cell Death in
Dopaminergic SH-SY5Y Cells via Stimulating
Mitochondrial Dysfunction
Huey Sze Leong 1,2 , Morgan Philp 1 , Martin Simone 2, Paul Kenneth Witting 2,* and
Shanlin Fu 1,*
1 Centre for Forensic Science, School of Mathematical and Physical Sciences, University of Technology Sydney,
Ultimo, NSW 2007, Australia; huey.s.leong@student.uts.edu.au (H.S.L.); morgan.philp@uts.edu.au (M.P.)
2 Discipline of Pathology, Charles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health,
The University of Sydney, Camperdown, NSW 2006, Australia; msim6013@uni.sydney.edu.au
* Correspondence: paul.witting@sydney.edu.au (P.K.W.); shanlin.fu@uts.edu.au (S.F.);
Tel.: +61-2-9114-0524 (P.K.W.); +61-2-9514-8207 (S.F.)
Received: 31 December 2019; Accepted: 16 February 2020; Published: 18 February 2020


Abstract: Increasing reports of neurological and psychiatric complications due to psychostimulant
synthetic cathinones (SCs) have recently raised public concern. However, the precise
mechanism of SC toxicity is unclear. This paucity of understanding highlights the need to
investigate the in-vitro toxicity and mechanistic pathways of three SCs: butylone, pentylone,
and 3,4-Methylenedioxypyrovalerone (MDPV). Human neuronal cells of SH-SY5Y were cultured
in supplemented DMEM/F12 media and differentiated to a neuronal phenotype using retinoic acid
(10 µM) and 12-O-tetradecanoylphorbol-13-acetate (81 nM). Trypan blue and lactate dehydrogenase
assays were utilized to assess the neurotoxicity potential and potency of these three SCs. To investigate
the underlying neurotoxicity mechanisms, measurements included markers of oxidative stress,
mitochondrial bioenergetics, and intracellular calcium (Ca2+), and cell death pathways were
evaluated at two doses (EC15 and EC40), for each drug tested. Following 24 h of treatment,
all three SCs exhibited a dose-dependent neurotoxicity, characterized by a significant (p < 0.0001 vs.
control) production of reactive oxygen species, decreased mitochondrial bioenergetics, and increased
intracellular Ca2+ concentrations. The activation of caspases 3 and 7 implicated the orchestration
of mitochondrial-mediated neurotoxicity mechanisms for these SCs. Identifying novel therapeutic
agents to enhance an altered mitochondrial function may help in the treatment of acute-neurological
complications arising from the illicit use of these SCs.
Keywords: mitochondrial dysfunction; calcium dysregulation; apoptosis; synthetic cathinones;
SH-SY5Y
1. Introduction
Synthetic cathinones (SCs) have emerged as popular supplements to “traditional” drugs
of abuse, such as cocaine, 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy or “Molly”),
and methamphetamine (meth), due to their psychostimulant and entactogenic effects [1]. These illicit
psychostimulants, often labeled as “not for human consumption”, are also marketed as “legal highs”,
“bath salts”, “plant food”, and “research chemicals” to evade scrutiny and detection by law enforcement
agencies. Their relatively low cost, ease of internet purchases, and the lack of control over clandestine
drug manufacturers have greatly contributed to the explosion of these drugs in the recreational drug
scene [2].
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3,4-Methylenedioxypyrovalerone (MDPV) (chemical structure shown in Figure 1) is one of the
most prevalent SCs found on the illegal drug market [3], with butylone and pentylone (Figure 1)
being identified as substitute drugs among the “legal highs” [4–9]. Powders, pills, and tablets sold as
“Molly” to electronic dance music attendees have also been found to be adulterated with butylone and
pentylone [10–12].
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Figure 1. Chemical structures of three synthetic cathinones (SCs): (A) butylone, (B) pentylone, and 
(C) 3,4-Methylenedioxypyrovalerone (MDPV). Table: Estimated pKa values (measure of ionization) 
calculated using MarvinSketch software (https://chemicalize.com/), XLogP3-AA (measure of 
lipophilicity), molecular weight (MW), polar surface area (PSA), and hydrogen bond donors (HBD) 
of (A) butylone, (B) pentylone, and (C) MDPV. Data were obtained from the PubChem Compound 
Database (https://www.ncbi.nlm.nih.gov/pccompound/56843046; 60208608; 20111961). Optimal 
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Figure 1. Chemical structures of three synthetic cathinones (SCs): (A) butylone, (B) pentylone,
and (C) 3,4-Methylenedioxypyrovalerone (MDPV). Table: Estimated pKa values (measure of
ionization) calculated using MarvinSketch software (https://chemicalize.com/), XLogP3-AA (measure of
lipophilicity), molecular weight (MW), polar surface area (PSA), and hydrogen bond donors (HBD) of (A)
butylone, (B) pentylone, and (C) MDPV. Data were obtained from the PubChem Compound Database
(https://www.ncbi.nlm.nih.gov/pccompound/56843046; 60208608; 20111961). Optimal penetration of
BBB: XLogP3-AA ranged from 1 to 4, MW < 450 Da, PSA < 90 Å2, and HBD < 3.
SCs act as central nervous stimulants via escalating neurotransmitters’ concentration. Butylone and
pentylone display hybrid transporter activity, characterized by inhibition effects at the dopamine transporter,
DAT (more potent for pentylone), but substrate effects at the serotonin transporter, SERT (more potent
for butylone) [13]. MDPV, on the other hand, is known for its potent inhibition effects at DAT and NET,
but not as a substrate releaser [14]. SCs are readily self-administered, with pentylone and MDPV exhibiting
a higher reinforcing efficacy, suggesting considerable potential for compulsive use [15,16].
The abuse of SCs poses serious public health concerns due to their high addiction potential and
increasing number of fatalities [17,18]. Severe intoxications and death cases have been linked to the usage of
butylone, pentylone, and MDPV [19–25], and the majority of cases have been connected to neuropsychiatric
and neurological complications associated with SC toxicity [26,27]. In addition to the direct SC neurotoxicity
effects, potential interactions, such as hyperthermia, toxic metabolites, excitoxicity, and neuroinflammation,
may also contribute to SC-induced neurotoxicity [28]. In this study, the primary focus will be on the
direct neurotoxicity effects that are potentiated by dopaminergic neuron signaling. Preclinical studies have
suggested the potential neuronal damage induced by SCs [29]. Studies have also documented neurotoxic
effects of synthetic cathinones in utero and early life exposure [30,31]. More recently, the repeated binge-like
administration of MDPV in rats showed evidence of neurodegeneration [32]. Previous in-vitro studies
have revealed the neurotoxic potential of several SCs [33–38], but the neurotoxicity potential of butylone
and pentylone has remained unexplored. In recent years, oxidative stress and mitochondrial dysfunction
mechanisms have been identified as significant contributors to SC-induced neurotoxicity [36,37,39,40].
However, the role of neuronal calcium signaling in mitochondrial dysfunction and the induction of
neurotoxic cascades for SCs is scarce. The paucity of scientific research and understanding of neurotoxic
mechanisms determined the aims of the study.
The present study aimed to evaluate the neurotoxicity potential and potency of butylone and
pentylone in relation to MDPV using the well-established SH-SY5Y cell line that can be differentiated
into a dopaminergic neuronal phenotype [41]. It also aimed to define the role of these SCs in promoting
oxidative stress and mitochondrial dysfunction and altering calcium (Ca2+) levels as a plausible
mechanistic pathway of neurotoxicity in cultured neurons.
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2. Results
2.1. Butylone, Pentylone, and MDPV Elicited Neurotoxicity with Different Potencies
After 24 h of drug treatment, all of the SCs displayed a dose-dependent toxicity, whereby increasing
the drugs’ dosage increased the percentage of cell death of dopaminergic neuronal SH-SY5Y cells
(Figure 2A–C). Both the trypan blue (TB) assay and lactate dehydrogenase (LDH) assay produced
similar dose-response curves and EC50 values for all SCs. Butylone and pentylone had higher EC50
values when compared to MDPV. In order to elucidate the possible mechanisms underlying the
SC-elicited neurotoxicity, EC15 and EC40 doses were chosen for subsequent studies.
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EC40 after 24 h of drug treatment (Figure 4A–F). The OCR for basal and maximal respiration decreased 
markedly (**** p < 0.0001 vs. control) and the decreased OCR was found to be dose-dependent for 
pentylone and MDPV. The OCR for proton leak and non-mitochondrial respiration was also found 
to decrease significantly when cultured SH-SY5Y cells were treated with the EC40 dose (**** p < 0.0001 
vs. control). Furthermore, the OCR for the spare respiratory capacity reduced markedly at the EC40 
dose (**** p < 0.0001 vs. control) and was dose-dependent for pentylone and MDPV. Collectively, 
these findings show that all three SCs at EC40 doses profoundly impaired the mitochondrial function 
by the disruption of respiration in dopaminergic neuronal SH-SY5Y cells. 
Figure 3. Intracellular levels of reactive oxygen species (ROS) after 2, 4, 6, and 24 h treatment of EC15
and EC40 for (A) butylone, (B) pentylone, and (C) MDPV. Data are Mean ± SD obtained from three
independent experiments. Different to the control; **** p < 0.0001 and *** p < 0.001.
2.3. Butylone, Pentylone, and MDPV Compromised Mitochondrial Bioenergetics
The production of ROS is often linked to mitochondrial respiratory chain dysfunction.
The Optimized Seah rse Mito Str ss assay was used to assess key parameters of mitochondrial
bioenergetics by measuring th oxygen consumption rate (OCR) of cells. This was performe by
sequential compound injections that targeted co onents of the electron transport chain (ETC) in the
mitochondria. All of the SCs reduced mitochondrial respiration ( xpressed by OCR) and increased
it ri l stress levels in cultured SH-SY5Y cells relative to the control at both doses EC15 an
EC40 after 24 h of drug tr atment (Figure 4A–F). Th OCR for basal and maxim l respiration decrease
markedly (**** p < 0.0001 vs. control) and the decreased OCR w s found to be dose-dependent for
pentylone and MDPV. The OCR for proton leak and non-mitochondrial respiration was also found to
d crease sig ificantly when cultured SH-SY5Y cells were treated with the EC40 dose (**** p < 0.0001 vs.
c ntrol). Furthermore, the OCR for the spare respiratory capacity reduced marke ly at the EC4 dose
(**** p < 0.0001 vs. control) and was dos -dependent for pentylone an MDPV. Collectively, these
findings show that all three SCs at EC40 doses profoundly impaired the mitochondrial function by the
disruption of respiration in dopaminergic neur nal SH-SY5Y cells.
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respiration (#### p < 0.0001 vs. EC15 pentylone and EC15 MDPV), (iv) non-mitochondrial respiration,
and (v) spare respiratory capacity (#### p < 0.0001 vs. EC15 pentylone, and ## p < 0.01 vs. EC15
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Impairment of the mitochondrial ETC function often leads to a subsequently compromised
bioenergetics balance. To further confirm that butylone-, pentylone-, and MDPV-induced mitochondrial
inhibition cause the impairment of cellular bioenergetics, a highly sensitive luminescence-based assay
was employed to assess the intracellular adenosine triphosphate (ATP) levels in cells. After 24 h
of drug treatment, all of the SCs stimulated significant intracellular ATP depletion when cells were
exposed to SCs at both EC15 and EC40 doses (all values significantly decreased relative to the control;
100% value corresponding to 11.4 mM/mg protein, Figure 5). Therefore, the residual ATP levels
in cultured SH-SY5Y cells determined for butylone, pentylone, and MDPV (administered at their
corresponding EC15 doses) were 23.5 ± 10.0%, 15.8 ± 15.5%, and 23.0 ± 22.5%, respectively. ATP levels
were further reduced to 8.5 ± 16.5%, 6.2 ± 17.8%, and 9.5 ± 12.9% at EC40 doses for butylone, pentylone,
and MDPV, respectively.
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2.4. Butylone, Pentylone, and DPV Altered Neuronal Ca2+ Homeostasis
Direct i aging and easure ent of Ca2+ provides i portant insights into the regulation of
intracellular Ca2+ in neurons. Treatment with drugs for 24 h significantly changed the neuronal
phenotype of branched dendrites (triangular arro head, Figure 6A) to that of rounded shaped cells
ith neurite retraction (Figure 6B–D). In the controls (no drug treat ent), a focal distribution of Ca2+
fluorescence was detected (filled arrow, Figure 6A), while a mixture of a focal and dispersed cytoplasmic
Ca2+ distribution (broken arrow) was detected in cells treated with SCs at EC15 concentrations
(Figure 6B–D). The dispersion of Ca2+ fluorescence was observed as early as 8 h after drug treatment,
with an increasing Ca2+ fluorescence intensity occurring in a time-dependent anner and reaching a
steady state between 12 and 22 h.
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100 µm) at different time points (8, 12, and 22 h) after drug treatments. Triangular arrowhead shows
cell axons, the filled arrow shows the focal distribution, and the broken arrow shows the dispersed
distribution of Cal-520 AM staining. (E) Quantification of Cal-520 AM fluorescence after 24 h of
treatment of EC15 and EC40 for butylone, pentylone, and MDPV. Data shown in panel E are Mean ± SD
obtained from four independent experiments. #### p < 0.0001 vs. EC15 butylone, EC15 pentylone and
EC15 MDPV. Different to the control; **** p < 0.0001.
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The quantification of intracellular Ca2+ showed that the intracellular Ca2+ levels increased
significantly 24 h after drug treatment (Figure 6E). Intracellular Ca2+ levels in cells exposed to butylone,
pentylone, and MDPV (administered at corresponding EC15 doses) were 292.3 ± 8.5%, 350.1 ± 11.0%,
and 543.2 ± 7.6%, respectively. Intracellular Ca2+ was further increased to 430.7 ± 11.5%, 489.5 ± 6.8%,
and 690.9 ± 5.9% at EC40 doses for butylone, pentylone, and MDPV, respectively. The increased
intracellular Ca2+ concentrations were dose-dependent for all SCs (#### p < 0.0001 vs. EC15).
2.5. Butylone, Pentylone, and MDPV Induce an Apoptotic Cell Death Pathway
To investigate whether SC neurotoxicity leads to mitochondrial programmed cell death,
measurement of the apoptosis executioner caspases 3 and 7 was performed. Caspase cleavage
of the proluminescent substrate liberates free aminoluciferin that is consumed by luciferase to generate
a glow-type luminescent signal. The signal produced is proportional to the caspase 3 and 7 activity.
The administration of butylone, pentylone, and MDPV promoted caspase 3 and 7 activation in
cultured SH-SY5Y cells 24 h after treatment (Figure 7). Caspase activation values in cells exposed to
butylone, pentylone, and MDPV (administered at their corresponding EC15 doses) were 392.0 ± 6.2%,
372.0 ± 6.8%, and 253.1 ± 10.8% vs. the control, respectively. Caspase activation was further increased
to 468.4 ± 16.7% and 342.0 ± 13.5% in cells treated with EC40 doses for butylone and MDPV, respectively,
but decreased to 200.0 ± 20.5% at EC40 doses for pentylone. Both butylone and MDPV stimulated a
dose-dependent increase in caspase activity (#### p < 0.0001 vs. EC15).
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3. Discussion
The present findings highlight the potential neurotoxicity potency associated with the abuse
of butylone, pentylone, and MDPV. The neurotoxicity of these SCs resulted in a raft of cellular and
molecular level effects, including the accumulation of ROS production, mitochondrial dysfunction,
and the alteration of Ca2+ homeostasis that finally led to apoptotic cell death. The increased incidence
of neurological and psychiatric changes involving cognitive impairments and mental illnesses after SC
use further demonstrated their neurotoxicity [42]. A growing number of studies have suggested that
SCs induce neurocognitive dysfunction among acute and long-term users [32]. Currently, there is no
antidote for acute intoxications of SCs, although behavioral-based and lifestyle interventions, together
with seemingly promising pharmacotherapy drug treatment, are gaining more attention.
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Our study demonstrates that SCs exert significant neurotoxic effects on cultured dopaminergic
neuronal SH-SY5Y cells. The dose-dependent neurotoxicity pattern demonstrated showed the
detrimental impact of these SCs upon exposure when administered. Overall, butylone appeared to be
less potent when compared to pentylone and MDPV (EC50: butylone 6.39, pentylone 4.44, and MDPV
3.61 mM). The orders of drug potency determined by both TB and LDH assays were similar (MDPV
≈ pentylone > butylone). These results were consistent with previous studies conducted, where an
increasing cytotoxicity was documented for drugs with longer alkyl side-chains. Such elongation
is thought to increase the lipophilicity (XLogP3-AA values, Figure 1: butylone 1.9, pentylone 2.3,
and MDPV 3.3) and hence its ability to penetrate the cell membrane, in order to facilitate cell
death [43,44]. Drug potency is also influenced by drug permeability of the blood–brain barrier (BBB).
All the SCs’ physicochemical properties were within the optimal ranges (Figure 1), suggesting the
ease with which these SCs can cross the BBB [45,46] and exert their pharmacological effects on the
monoamine transporters. However, the relative neurotoxic potencies (demonstrated by the difference
in EC50 values) shown did not correlate with the values of previously reported DAT inhibition
potencies [47,48], indicating that the neurotoxicity of butylone, pentylone, and MDPV seemed to be
independent of DAT-mediated uptake. These findings are in agreement with an independent study
conducted by Valente et al., whereby no protective effect of the GBR 12909 DAT inhibitor was observed
for MDPV-induced neurotoxicity [36]. It is not known whether these SCs gain entry into cells via
other carrier-mediated uptake or by diffusion, demonstrating that the precise underpinnings of cellular
uptake are not fully understood and require future investigation.
The formation of toxic reactive oxygen and nitrogen species has been implicated in the promotion
of neuronal cell death. Recently, there has been increasing evidence that ROS are responsible for
SC-related neuronal damage. In this study, the rapid and time-dependent production of intracellular
ROS (Figure 3) was observed, indicative of a central role for oxidative stress involvement in
the neurotoxicity mediated by butylone, pentylone, and MDPV. ROS production following this
SC exposure might be an early biochemical indicator that precedes neuronal cell death. It is
unclear why ROS production under these experimental conditions showed a time-dependent,
but not dose-dependent, increment for these SCs. However, the findings from this study are in
agreement with recent in-vitro studies whereby oxidative stress was found to be involved in the
mechanism of action of the SCs 4-Methylmethcathinone (4-MMC), 3,4-Methylenedioxymethcathinone
(MDMC), α-Pyrrolidinooctanophenone (α-POP), α-Pyrrolidinononanophenone (α-PNP), methylone,
3-Fluoromethcathinone (3-FMC), and MDPV [36,37,39,40,43,49,50]. Although the mechanism
underlying ROS production remains to be elucidated, it is clear that intracellular ROS promote
oxidative stress and potentiate mitochondrial dysfunction in neuronal cells.
Mitochondria, the major regulators of cellular energy metabolism, have been recognized as the
primary source of intracellular ROS and the key player in amphetamine-induced stress [51]. They act as
energy generators in cells via oxidative phosphorylation and ATP production. Mitochondrial respiration
impairment has been implicated in neuronal death and several neurodegenerative diseases. In the
basal state, mitochondrial oxygen consumption is mainly driven by ATP synthase. Drug treatment
at an EC15 dosage of butylone, pentylone, and MDPV led to a 41–76% inhibition of basal OCR in
comparison to the control, suggesting significantly altered ATP consumption, even at low doses of
SCs. Following the addition of oligomycin when evaluating the mitochondrial coupling, the OCR
decreased and the remaining mitochondrial oxygen consumption was predominantly driven by the
proton leak across the inner membrane. A substantial reduction of proton leak at EC40 doses (63–67%
from the control), indicated that mitochondria were severely damaged and uncoupled. The addition of
carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone, FCCP dissipated the proton gradient across
the mitochondrial inner membrane, uncoupling electron transport from oxidative phosphorylation
and hence facilitating measurement of the maximal OCR. A significant reduction of the maximal
respiration capacity (33–66% from the control) signified dysfunction in the respiratory complexes and
depletion of the mitochondrial membrane potential, which is crucial for the functional integrity of
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mitochondrial ETC. The final addition of rotenone and antimycin A shut down the mitochondrial
ETC function, enabling the measurement of non-mitochondrial oxygen consumption. A significant
reduction of non-mitochondrial oxygen consumption at both doses (41–58% from the control) implied
an overall slowing down of cell metabolism due to energy stress. The spare respiratory capacity,
the major determinant of the cells’ survival under the maximal physiological or pathophysiological
condition, is a critical factor in maintaining the ATP-generating capacity reserve. At the EC40 dose,
the level of OCR, a surrogate for the spare respiratory capacity, was reduced significantly (64–89%
from the control), further confirming the inhibition of ETC by these SCs. Generally, the reduction
of mitochondrial respiration demonstrated by the significantly decreased OCR of the individual
parameters at EC40 doses (Figure 4A–F) compared to controls, indicated that butylone, pentylone,
and MDPV may inhibit multiple components of the ETC, resulting in the impairment of mitochondria.
Mitochondrial impairment upon MDPV exposure has been reported in SH-SY5Y cells using end-point
measurement, such as mitochondrial membrane depolarization [36]. Up to now, there is only one
other respiration kinetic study that has described the involvement of the mitochondrial inhibition of
complexes within the ETC for SC-induced neurotoxicity [39]. In this study, the effects of butylone,
pentylone, and MDPV were identified and quantified for impairment of the mitochondrial ETC
function, leading to the mitochondrial dysfunction of dopaminergic neuronal SH-SY5Y cells.
The inhibition of mitochondrial ETC complexes’ activity by these SCs might be the key player
in the neurotoxicity, oxidative stress, and consequent disruption of the mitochondrial bioenergetics
balance. Impaired energy metabolism that results in ATP depletion as a consequence of mitochondrial
dysfunction has been associated with SC-induced toxicities [36,52,53]. The significantly decreased
residual intracellular ATP content relative to the control (Figure 5) in this study supports the fact
that butylone, pentylone, and MDPV treatment induced severe cellular energy deficits resulting from
mitochondrial impairment in dopaminergic neuronal SH-SY5Y cells. The mechanisms by which these
SCs may cause energy impairment remain to be identified. Overall, these data support that a decreased
mitochondrial function, specifically the impairment of oxidative phosphorylation through the depletion
of energy stores, is critically linked with butylone-, pentylone-, and MDPV-induced neurotoxicity.
Mitochondria also participate in Ca2+ buffering, together with the endoplasmic reticulum,
in maintaining Ca2+ homeostasis. A time- (Figure 6B–D) and dose-dependent (Figure 6E) increase
of intracellular Ca2+ induced by butylone, pentylone, and MDPV after treatment verified the alteration
of intracellular Ca2+ regulation. Dysregulated Ca2+ release from intracellular reservoirs combined with
influx from the extracellular domain could lead to a sustained increase in intracellular Ca2+ over time.
Meth-mediated neuronal damage involving the disruption of Ca2+ homeostasis has been reported [54],
but studies on how Ca2+ is linked to SC-induced neurotoxicity are scarce. Our work extends the link to SCs
disrupting neuronal Ca2+ homeostasis that is linked downstream to mitochondrial dysfunction. A further
investigation of the exact mechanisms explaining how these SCs contribute to the dysregulation of Ca2+
homeostasis, including the identity of protein transporters that are affected, is warranted.
Calcium is involved in many aspects of neuronal physiology, as well as pathophysiology, where
Ca2+ homeostasis disruption triggered the initiation of the intrinsic apoptotic cell death pathway.
The activation of both intrinsic and extrinsic apoptotic pathways has been previously reported for
MDPV [36,53], but the death mechanism has remained unknown for both butylone and pentylone.
The data obtained in this study indicate that all of the SCs stimulated an apoptotic cell death pathway
through the activation of effector caspases 3 and 7. Regardless of the type of activation, the signal sources
ultimately activated the common downstream mechanisms, specifically the apoptosis executioner
caspase 3 and 7 cascade (Figure 7).
Although the EC15 and EC40 SC concentrations used in this study are much higher than commonly
reported concentrations found in blood (up to 0.09 mM) of post-mortem (PM) cases [19,20,23], they are
in good agreement with previously conducted mechanistic in-vitro studies using neuronal cell lines.
For example, other researchers have employed ~1.2 and 1.7 mM MDPV in SH-SY5Y cells [36], 1–4 mM
3-FMC in HT22 cells [40], 0.25–20 mM for a series of 13 synthetic cathinones in SH-SY5Y cells [55],
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and 0.01–2.5 mM MDPV in SH-SY5Y cells [56]. Moreover, PM blood concentrations are usually lower
than the peak concentrations expected after the initial drug intake, so are not a useful measure of the
maximal drug concentration. Furthermore, it is worth considering that these SCs can accumulate in
the intracellular compartment. Hence, it can be assumed that the PM blood levels reported likely
underestimate the circulating and intracellular concentrations of SCs. Interestingly, PM findings have
shown that the tissue levels of the drug MDMA can be up to 30 times higher in the human brain [57],
consistent with the notion that these drugs can traverse the blood–brain barrier (BBB) and accumulate
in the brain. Precise prediction of the SC concentration in the brain is unclear and complicated due
to the different administration routes and BBB permeabilities of these drugs (which may or may not
be compromised in abusers), as well as possible PM SC redistribution [58] and/or metabolism [59].
Moreover, it is important to note that the immortalized dopaminergic neuronal cell line SH-SY5Y can
be more resistant to the cytotoxicity of added drugs. One possibility of the more resistant differentiated
SH-SY5Y cellular phenotype may be linked to the up-regulated expression of Nrf2 proteins that provide
an enhanced capacity to buffer the oxidative insults [60]. Hence, the pathophysiological outcomes from
this study are tempered by the drug dose required to elicit responses in this cell culture model. While it
is unclear precisely how the actual dose of SCs used in this study is pharmacologically or even clinically
relevant, or indeed whether the dose range employed in this work can be translated to the human
usage of recreational SCs, particularly at the time of administration, it remains important to understand
the type of damage elicited in different cell types that may be vulnerable to these drugs. This, in turn,
may provide some understanding on the potential for similar doses in humans (if achievable) to cause
neuronal cell damage via mechanisms that involve mitochondrial dysfunction leading to a decreased
cell viability. For the above reasons, the neurotoxicity findings observed in this in-vitro system should
be repeated in cultures of primary neuronal cell cultures and in-vivo models to ascertain the sensitivity
to a lower SC dose as a further model of neuronal toxicity for these drugs.
The chronic use of psychostimulants has been associated with cognitive dysfunction and various
neuropsychological consequences, such as impaired impulse control, working memory, decision making,
attention, and motor coordination [32,61,62]. In addition, meth use has been linked to an increased risk
of developing neurodegeneration diseases, such as Parkinson’s disease (PD) [63]. Repeated long-term
acute exposure of meth has been associated with the neurodegeneration of dopaminergic neurons,
reflecting the degeneration pattern observed in PD patients [64]. These epidemiological findings suggest
that only a very small proportion of meth users are subsequently diagnosed with PD and the usage
of dopamine substitution therapy among meth users is still in a premature investigational stage [65].
Given the chemical structure similarities of the SCs to meth, it is reasonable to postulate that long-term
high-dosage exposure of these SCs might also result in Parkinson-like development. Reports have
shown that SC users have also been associated with homelessness [66] or lower socioeconomic areas [67],
where a greater risk of poor health with a poor antioxidant system further enhanced their susceptibility
to SC toxicity. Behavioral factors such as physical exercise [68] and healthy dietary lifestyle measures via
an increased anti-oxidative capacity have been shown to be a promising approach in the management of
psychostimulant addiction [69]. There is currently no remedy for SC intoxication, except for supportive
care [70]; however, the oxidative stress mechanistic pathway suggests the possibility of efficacious
antioxidant pharmacotherapies for attenuating SC-induced ROS production [71]. Considering that
mitochondrial dysfunction plays a critical part in SC-induced neurotoxicity, the enhancement of
mitochondrial function [72] and mitochondrial transplantation [73] have received attention as strategies
that might ameliorate the associated mitochondrial neurodegeneration. Moreover, the development of
therapeutic strategies that stabilize neuronal Ca2+ homeostasis by targeting the calcium channels may
also be capable of preventing neurotoxicity induced by these SCs [74].
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4. Materials and Methods
4.1. Chemical Synthesis
Hydrochloride salts of butylone, pentylone, and MDPV were synthesized in-house with a purity
greater than 98%. The synthesis of salts involved a multiple-step reaction sequence: Grignard reaction
of piperonal, oxidation, α-bromination, and nucleophilic substitution with methylamine (for butylone
and pentylone HCl) and pyrrolidine (for MDPV HCl). The final product salt was obtained following
extraction and HCl work-up. The salts were fully characterized by proton (1H-NMR) and carbon
(13C-NMR) nuclear magnetic resonance spectroscopy, gas chromatography-mass spectrometry (GC-MS),
Fourier-transform infrared (FTIR) spectroscopy, and ultraviolet (UV) spectroscopy. Butylone HCl:
1H-NMR (500 MHz, D2O) δ, ppm: 7.705–7.686 (dd, 3JHH = 8.25 Hz, 4JHH = 1.25 Hz, 1H), 7.481–7.478 (d,
4JHH = 1.5 Hz, 1H), 7.045–7.028 (d, 3JHH = 8.5 Hz, 1H), 6.134–6.130 (d, 2JHH = 2.0 Hz, 2H), 5.025–5.003
(t, 3JHH = 5.5 Hz, 1H), 2.741 (s, 3H), 2.131–2.040 (m, 2H), 0.889–0.859 (t, 3JHH = 7.5 Hz, 3H); 13C–NMR
(125 MHz, CD3OD) δ, ppm: 194.114, 153.006, 148.401, 128.603, 125.986, 108.719, 107.987, 102.687, 62.641,
31.494, 23.187, 8.385; EI (m/z, %): 221(M+,0), 219(2), 149(11), 121(7), 72(100), 70(30); FTIR (ATR) νmax,
cm−1: 2909 (C-H stretch), 2689 and 2475 (asym. and sym. NH2+ stretches), 1674 (C=O stretch), 1602 and
1452 (C=C stretch), 1252 (C-C=O stretch), 1035 (C-O stretch), 880 and 802 (1,2,4-trisubstituted benzene);
UV (H2O) λmax, nm: 236, 282, 321. Pentylone HCl: 1H-NMR (500 MHz, D2O) δ, ppm: 7.696–7.679
(d, 3JHH = 7.5 Hz, 1H), 7.467 (s, 1H), 7.040–7.023 (d, 3JHH = 8.5 Hz, 1H), 6.129 (s, 2H), 5.024–5.002
(t, 3JHH = 5.5 Hz, 1H), 2.734 (s, 3H), 2.031–1.916 (m, 2H), 1.365–1.218 (m, 2H), 0.874–0.845 (t, 3JHH =
7.25 Hz,3H); 13C-NMR (125 MHz, CD3OD) δ, ppm: 194.334, 153.024, 148.416, 128.728, 126.008, 108.726,
107.979, 102.706, 61.799, 32.142, 31.566, 17.295, 13.855; EI (m/z, %): 235(M+,0), 192(24), 164(8), 149(100),
121(20), 91(4), 65(9); FTIR (ATR) νmax, cm−1: 2963 (C-H stretch), 2744 and 2481 (asym. and sym. NH2+
stretches), 1675 (C=O stretch), 1603 and 1453 (C=C stretch), 1256 (C-C=O stretch), 1033 (C-O stretch),
863 and 806 (1,2,4-trisubstituted benzene); UV (H2O) λmax, nm: 236, 282, 321. MDPV HCl: 1H-NMR
(500 MHz, D2O) δ, ppm: 7.725–7.709 (d, 3JHH= 8.0 Hz, 1H), 7.496 (s, 1H), 7.061–7.044 (d, 3JHH = 8.5 Hz,
1H), 6.148–6.142 (d, 4JHH = 3.0 Hz, 2H), 5.122 (br. s, 1H), 3.455–3.284 (m, 4H), 2.128–1.999 (m, 6H),
1.248–1.147 (m, 2H), 0.850–0.821 (t, 3JHH = 7.25 Hz, 3H); 13C-NMR (125 MHz, CD3OD) δ, ppm: 194.334,
153.024, 148.416, 128.728, 126.008, 108.726, 107.979, 102.706, 61.799, 32.142, 31.566, 24.389, 17.295, 13.855;
EI (m/z, %): 275(M+,0), 149(5), 126(100), 96(4), 55(5); FTIR (ATR) νmax, cm−1: 2969 (C-H stretch), 2610
(NH+ stretch), 1684 (C=O stretch), 1609 and 1435 (C=C stretch), 1253 (C-C=O stretch), 1033 (C-O),
867 and 807 (1,2,4-trisubstituted benzene); UV (H2O) λmax, nm: 237, 285, 324.
4.2. Cellular Studies
The CountessTM cell counting chamber slide and TB Stain 0.4% w/v were purchased from Invitrogen
(Eugene, OR, USA). The LDH cytotoxicity assay kit was purchased from Cayman Chemical (Ann
Arbor, MI, USA). The DCFDA/H2DCFDA (2′,7′-dichlorofluorescin diacetate)—Cellular reactive oxygen
species (ROS) detection assay kit and Cal-520 AM were purchased from Abcam (Cambridge, UK).
Seahorse Extracellular Flux (XF) 96 cell culture microplates, the XF 96 assay kit, the Cell Mito Stress Test
Kit, XF calibrant, XF Base Medium, and the XF96 Analyzer were obtained from Seahorse Bioscience
(North Billerica, MA, USA). The ATPlite luminescence assay system was purchased from Perkin Elmer
(Waltham, MA, USA). The Caspase-Glo® 3/7 assay was purchased from Promega (Madison, WI, USA).
T75 tissue culture flasks, and 96-well and 6-well cell culture plates were purchased from Corning
(Corning, NY, USA). The phosphate buffered saline (PBS) tablet, copper (II) sulfate solution (CuSO4,
4% w/v), bicinchoninic acid (BCA), phorbolester 12-O-tetradecanoylphorbol-13-acetate (TPA), retinoic
acid (RA), and all cell culture materials were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Milli-Q water (18.2 MΩ cm−1) was obtained from Sartorius (Göttingen, Germany). The Countess™ II
automated cell counter was purchased from Thermo Fisher Scientific (Waltham, MA, USA). The Axio
Vert.A1 inverted microscope was purchased from Zeiss (Jena, Germany). Centrifuge 5415 R and 5810 R
were purchased from Eppendorf (Hamburg, Germany). The Orbit P4 digital microtube and microplate
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orbital shaker was obtained from Labnet (Edison, NJ, USA). The IncuCyte® system was purchased
from Essen BioScience (Ann Arbor, MI, USA). The Infinite® M200 Pro plate reader was purchased
from Tecan (Männedorf, Switzerland).
4.3. Cell Culture
The human neuroblastoma SH-SY5Y cell line (ATCC, Manassas, VA, USA) was grown in a
T75 tissue culture flask containing Dulbecco’s Modified Eagle’s Medium (DMEM)/F-12 Ham mixtures
supplemented with 10% heat-inactivated fetal bovine serum (HI-FBS), l-glutamine (2 mM), a mixture
of penicillin/streptomycin (100 U/mL/100 µg/mL), and non-essential amino acid solution (NEAA, 1×).
Cells were cultured at 37 ◦C in a humidified atmosphere incubator containing 95% air and 5% CO2,
until 75–80% confluence. Media was changed every 2 to 3 days. Where required, cells were harvested
by subculture with media containing trypsin/EDTA (0.12% trypsin/ 0.02% EDTA w/v). The cells were
passaged over 8 passages (Passage 6–13) and counted under TB staining using an automated cell
counter. Cells were seeded in full media (10% HI-FBS) onto multi-well plates overnight at the required
density. Cells were differentiated to a dopaminergic neuronal phenotype by a previously reported
method, with slight modification [75], using 10 µM RA media (2.5% HI-FBS) for 3 days, followed by a
mixture of 10 µM RA and 81 nM TPA (2.5% HI-FBS) for another 3 days. General cell morphology was
monitored at regular intervals using phase contrast inverted microscopy.
4.4. Cytotoxicity Assays
Cells were sub-cultured and seeded at a density of 25,000 cells/cm2. Cells were then treated with
butylone, pentylone, and MDPV individually for 24 h at 37 ◦C. This exposure time was identical to
those used for other in-vitro studies involving similar SC doses [36,40,56,76,77]. Dose-response curves
for these SCs (1 to 10 mM) were determined using TB and LDH assays. The effective concentrations of
EC15, EC40, and EC50, that is, the concentration that induces 15%, 40%, and 50% cell death, respectively,
for each drug were determined from the dose-response curves. The calculated mean EC15 and
EC40 of butylone, pentylone, and MDPV (refer to tabulated data in Figure 1) were then used for
subsequent experiments.
4.5. TB Assay
Upon treatment, drug media containing non-adherent cells was transferred from the 6-well plate
into a 1.5 mL tube and centrifuged (200 relative centrifugal force, r.c.f; 6 min). Adherent cells were
harvested as described above and resuspended into the pellet cells obtained from the media fraction.
The total number of cells were then counted using an automated cell counter. Data were obtained from
three independent experiments. Background subtraction (untreated control) was performed for all
wells. Finally, the % cytotoxicity was calculated as the percentage of the ratio of non-viable cells to the
total number of cells.
4.6. LDH Assay
Upon treatment, a 96-well plate was centrifuged (400 r.c.f; 5 min). Next, 100 µL of the isolated
supernatant was transferred to another 96-well plate and each well was treated with 100 µL of reaction
mixture containing nicotinamide adenine dinucleotide (NAD+), lactic acid, iodonitrotetrazolium
salt (INT), and reconstituted diaphorase, prepared according to the manufacturer’s instruction.
Treated samples were incubated at 37 ◦C with shaking on an orbital shaker. After 30 min, absorbance
was measured at 490 nm with a Tecan plate reader. Data were obtained from four independent
experiments with background subtraction (media only) prior to determination of the % cytotoxicity,
as follows (Equation (1) below):
% Cytotoxicity of sample = (Asample − Aassay buffer)/(ATriton X−100 − Aassay buffer) × 100. (1)
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4.7. Measurement of Intracellular ROS
Levels of intracellular ROS were determined using a commercial kit, as per the manufacturer’s
instruction. Briefly, cells were seeded at a density of 50,000 cells/cm2 onto a 96-well black, clear-bottom
plate. Cells were rinsed with 1× buffer (provided in the kit) and incubated with 100 µL DCFDA
(25 µM) at 37 ◦C for 45 min in the dark. Cells were rinsed with 1× buffer before being treated with
each drug individually. Fluorescence was measured at Ex/Em: 485/535 nm with a Tecan plate reader
at different time points (2, 4, 6, and 24 h). Background subtraction (media only) was performed for
all wells. Data were obtained from four independent experiments and the data was expressed as a %
fold-change relative to the control.
4.8. Measurement of Mitochondrial Respiration
Cells were seeded at a density of 20,000 cells/80 µL well onto XF 96-well cell culture microplates.
Upon the individual treatment of each drug, media was replaced with XF base media with added
glucose (10 mM), sodium pyruvate (1 mM), and L-glutamine (2 mM), and kept in a non-CO2 incubator
at 37 ◦C for 1 h. Analysis of OCR was performed in a Seahorse XF96 analyzer, according to the
manufacturer’s instructions. Mitochondrial respiration kinetics using the Seahorse analyzer was
employed to provide valuable information regarding the extent of mitochondrial dysfunction in
response to butylone, pentylone, and MDPV. The measurement of OCR using the Seahorse analyzer
has been proven to be the most widely used technique in determining mitochondrial bioenergetics
dysfunction in cells [78]. OCR was measured in a basal condition, and following the injection of each
compound: ATP synthase inhibitor oligomycin (1 µM), the mitochondrial uncoupler FCCP (0.5 µM),
and a mixture of complex I + II inhibitors rotenone with antimycin A (1 µM + 1 µM). The mixture was
incubated for 3 min, followed by a 3 min lag-time for each cycle. Three measurements were taken for
each condition. Data were obtained from at least four independent experiments and normalized to %
confluence using the IncuCyte® system and standard software.
4.9. Measurement of Intracellular Adenosine Triphosphate (ATP)
Levels of intracellular ATP were determined using a commercial kit, as per the manufacturer’s
instructions. Briefly, cells were seeded at a density of 25,000 cells/cm2 onto a 96-well plate.
Following individual drug treatment, media was replaced with a mixture of 100 µL of PBS (0.01 M, pH
7.5) and 50 µL of mammalian cell lysis solution (provided in the kit). The mixture was mixed in an
orbital shaker (700 revolutions per min (r.p.m.); 5 min). In the dark, 50 µL of substrate, luciferase-lucerin
(provided in the kit), was added and shaken for another 5 min at 700 r.p.m. The plate was left in the
dark (10 min; 22 ◦C) and luminescence was measured with a Tecan plate reader. Intracellular ATP
levels were determined with a calibration curve that was obtained in parallel on the same plate using a
10 mM stock solution of reconstituted lyophilized ATP standard prepared in Milli-Q water. Data were
obtained from three independent experiments and normalized to the total protein using the BCA assay
method. Briefly, protein levels in the cell lysates were measured with 190 µL of CuSO4/BCA solution
(0.02% v/v) added to each well containing 10 µL of BSA standards or treated samples (5 µL of Milli-Q
water was added to 5 µL of sample). The mixture was incubated (37 ◦C; 25 min) and absorbance
was measured at 562 nm with a Tecan plate reader. Values were standardized against a BSA protein
standard curve generated on the same plate.
4.10. Real-Time Imaging and Measurement of Intracellular Ca2+
Cells were seeded at a density of 25,000 cells/cm2 onto a 96-well black, clear-bottom plate.
Cells were incubated with 100 µL of Cal-520 AM (5 µM) at 37 ◦C for 1 h and then allowed to equilibrate
to 22 ◦C for a further 30 min before treatment of the cells with individual drugs. Fluorescence was
measured at Ex/Em: 490/525 nm with a Tecan plate reader. Background subtraction (media only) was
performed for all wells. Data were obtained from four independent experiments and the data was
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expressed as a % fold-change relative to the control. Phase contrast and fluorescence images of cellular
Ca2+ were also acquired using a real-time imaging IncuCyte® system at different time points (8, 12,
and 22 h). Cal-520 AM was excited with a 440–490 nm filter and emitted fluorescence was collected
with a 504–544 nm filter (green channel). Images were captured using a 10x objective.
4.11. Measurement of Caspase 3 and 7 Activity
Cells were seeded at a density of 25,000 cells/cm2 onto 96-well white, clear-bottom plates. Upon the
individual treatment of each drug, media was replaced with 100 µL of 2.5% HI-FBS media. The plate
was allowed to equilibrate at 22 ◦C and 100 µL of Caspase-Glo® 3/7 reagent was then added and
the plate was incubated in the dark. The mixture was mixed in an orbital shaker (500 r.p.m., 30 s)
and further incubated at 22 ◦C for 1.5 h. Luminescence was measured with a Tecan plate reader.
Background subtraction (media only) was performed for all wells. Data were obtained from four
independent experiments and normalized to % confluence using the IncuCyte® system employing
standard software.
4.12. Data Analysis
Data was expressed as the mean ± standard deviation from at least three independent experiments.
For comparisons, data were analysed using one-way analysis of variance (ANOVA) followed by
Tukey’s test using Graph Pad Prism 7. Statistical significance was set at p < 0.05. EC50 values were
obtained from the dose-response curve. EC15 and EC40 values were calculated using Graph Pad
QuickCalcs. The XF mito stress test report generator automatically calculated the XF cell mito stress
test parameters from wave data that were exported to Excel.
5. Conclusions
The present study sheds light on the cellular and molecular mechanisms underlying the
neurotoxicity potency of butylone, pentylone, and MDPV. The apoptotic cell death pathway implicated
the orchestration of mitochondrial-mediated toxicity mechanisms via oxidative stress, a compromised
bioenergetics balance, and changes in Ca2+ homeostasis. Understanding the mechanisms underlying
these neurotoxic actions and related clinical manifestation is imperative in the management and
treatment of acute-neurological complications arising from SC addiction. The potential clinical
relevance of this study includes the demonstration that butylone, pentylone, and MDPV (i) trigger
neuronal apoptosis and stimulate (ii) increased intracellular Ca2+ and (iii) mitochondrial dysfunction,
leading to a loss in ATP, which is information that may be useful in understanding the detrimental
impact of these drugs. The findings in this study should be viewed as a model for understanding the
neurotoxic mechanisms that may play a role in the response of the human central nervous system to
SC exposure. Substantial work remains before safe and novel therapeutic agents may be developed
and translated for human use in the prevention of the devastating neurotoxic effects associated with
the abuse of these drugs.
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